W.G. Shaheen & Associates DBA Whitney & Co Sells 38,470 Shares of Kenvue Inc. (NYSE:KVUE)

W.G. Shaheen & Associates DBA Whitney & Co lessened its position in shares of Kenvue Inc. (NYSE:KVUEFree Report) by 9.6% during the 4th quarter, HoldingsChannel reports. The fund owned 360,498 shares of the company’s stock after selling 38,470 shares during the quarter. W.G. Shaheen & Associates DBA Whitney & Co’s holdings in Kenvue were worth $7,697,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. State Street Corp raised its position in shares of Kenvue by 16.8% during the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after acquiring an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Kenvue by 8.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock valued at $2,011,832,000 after purchasing an additional 7,115,374 shares during the last quarter. Holocene Advisors LP increased its holdings in Kenvue by 75.5% in the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock valued at $321,194,000 after purchasing an additional 5,975,392 shares during the last quarter. M&G PLC lifted its stake in Kenvue by 538.0% in the third quarter. M&G PLC now owns 4,341,172 shares of the company’s stock valued at $99,847,000 after buying an additional 3,660,730 shares during the period. Finally, FMR LLC boosted its holdings in Kenvue by 2.3% during the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after buying an additional 3,075,019 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Up 4.1 %

KVUE stock opened at $23.31 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a market capitalization of $44.68 billion, a P/E ratio of 43.97, a P/E/G ratio of 2.62 and a beta of 1.45. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The business has a 50-day moving average of $21.31 and a 200-day moving average of $22.20.

Kenvue (NYSE:KVUEGet Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, sell-side analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.52%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Citigroup cut their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. Canaccord Genuity Group cut their target price on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Barclays reduced their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Finally, UBS Group decreased their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and a consensus price target of $23.00.

Get Our Latest Report on KVUE

About Kenvue

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Further Reading

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUEFree Report).

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.